Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab

References

• All Y, Shah S. Infliximab induced SLE. Ann Intern Med 2002;137:625–626.
   Google Scholar
• Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11:753–755.
   PubMed Web of Science ®Google Scholar
• Charles PJ, Smeenk RJT, DeJong J, Feldmann M, Maini RN. Assessment of antibodies to double stranded DNA induced in RA patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a. Arthritis Rheum 2000;43:2383–2390.
   Google Scholar
• Paulus HD, Wiesner J, Bulpitt KJ, Patnaik M, Law J, Park GS, Wong WK. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment. J Rheum 2002;29:2513–2520.
   Google Scholar
• Fox RL. Sjogren's syndrome. In: Kelley WN, Harris Jr., WD, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Philadelphia: Saunders, 1997. p 951–954.
   Google Scholar
• Pinals RS. Felty's syndrome Textbook of rheumatology. Philadelphia: Saunders, 1997. p 951–954.
   Google Scholar
• Enzenauer RJ, West SG, Rubin RL. D-penicillamine induced lupus erythematosus. Ann Rheum Dis 1990;33: 1582–1583.
   Google Scholar
• Gunnarsson I, Nordmark B, Bakri AH, Larsson GP, Forslid J, Klareskog L, Ringertz B. Development of lupus related side effects in patients with early rheumatoid arthritis during sulphasalazine treatment: The role of IL-10 and HLA. Rheumatology 2000;39: 886–893.
   Google Scholar
• Marza-Ortega H, Misbah S, Emery P. Minocycline induced autoimmune disease in rheumatoid arthritis: A missed diagnosis. J Rheumatol 2001;28:377–378.
   Google Scholar
• Hobbs RN, Clayton AL, Bernstein RM. Antibodies to the five histones and poly (adenosine diphosphate-ribose) in drug induced lupus: Implications for pathogenesis. Ann Rheum Dis 1987;46:408–409.
   Google Scholar
• Asherson RA, Zulman J, Hughes GR. Pulmonary thrombo-embolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis 1989;148:233–235.
   Google Scholar
• Elkayam O, Levartovsky D, Brautbar C, Yaron M, Burke M, Vardinon N. Clinical and immunological study of 7 patients with minocycline induced autoimmune phenomena. Am J Med 1998;105: 484–487.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.
   PubMed Web of Science ®Google Scholar
• De Rycke L, Kruithof E, Van Damme N, Hoffman IA, Van den Bossche N, Van den Bosche F, Veys EM, de Keyser F. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 2003;48:1015–1023.
   Google Scholar
• Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid arthritis treated with etanercept or conventional combination therapy: Direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358–361.
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Assaloni R, Di Poi E, Gremese E, de Marchi G, Fabris M. Rescue of combination therapy failures using infliximab while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology (Oxf) 2002;41:1109–1112.
   PubMed Web of Science ®Google Scholar
• Rubin RL. Etiology and mechanisms of drug induced lupus. Curr Opin Rheumatol 1999;11:357–363.
   PubMedGoogle Scholar
• Choi HK, Slot MC, Pain G, Weissback CA, Niles JL, Merkel PA. Evaluation of ANCA seroconversion induced by minocycline, sulphasalazine or penicillamine. Arthritis Rheum 2000;43:2488–2492.
   PubMed Web of Science ®Google Scholar
• Strivastata M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, Ha E, Anhalt GJ, Provost TT, Nousari CH. Drug induced Ro/SSA positive cutaneous lupus erythematosus. Arch Dermatol 2003;139:45–49.
   Google Scholar
• Seitz M, Zwicker M, Villiger PM. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American college of rheumatology response groups to methotrexate. J. Rheumatol. 2003;30:28–35.
   Google Scholar
• Rodenburg RT, Ganga A, Van Lent PL, Van de Putte LB, Van Venrooij WJ. The anti-inflammatory drug sulphasalazine inhibits tumor necrosis factor expression in macrophages by inducing apoptosis. Arthritis Rheum 2000;43:1941–1950.
   Google Scholar
• Iwamoto Y, Nishimura F, Nakagawa M, Sugimoto H, Shihata K, Makin° H, Fukuda T, Tsuji T, Iwamoto M, Murayama Y. The effect of anti microbial periodontal treatment on circulating tumor necrosis factor-alpha and glycated hemoglobin levels in patients with type 2 diabetes. J Perodontol 2001;72: 774–778.
   Google Scholar
• Shanahan F, Niederlehner A, Carramanzana N, Anthon P. Sulphasalazine inhibits the binding of TNFa to its receptor. Immunopharmacology 1990;20:217–224.
   PubMed Web of Science ®Google Scholar
• Barrera P, Haagsma CJ, Boerbooms AM, Van Riel PL, Borm GF, Van de Putte LB, Van der Meer JW. Effects of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995;34:747–755.
   Google Scholar
• Jacob CO, McDevitt HO. Tumour necrosis factor a in murine autoimmune "lupus" nephritis. Nature 1988;331:356–358.
   PubMed Web of Science ®Google Scholar
• Gordon C, Ranges GE, Grenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor a in autoimmune NZB/NZW Fl mice. Clin Immunopathol 1989;52:412–434.
   Google Scholar
• Brennan DC, Yui MA, Wutrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand black/white mice: enhanced gene expression and acceleration of renal injury. J Immunol 1989;143:3470–3475.
   PubMed Web of Science ®Google Scholar
• Moore KJ, Yeh K, Naito T, Kelley VR. TNF-a enhances colony-stimulating factor-1 -induced macrophage accumu-lation in autoimmune renal disease. J Immunol 1996; 157:427–432.
   Google Scholar
• Deguchi Y, Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus prone mine. Chin Exp Immunol 1991;85:392–395.
   PubMed Web of Science ®Google Scholar
• Su X, Zhou T, Yang P, Edwards III, CK, Mountz JD. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum 1998; 41:139–149.
   PubMed Web of Science ®Google Scholar
• Frautel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor a blocking agent: Comment on the article by Pystesky and the letter from Aringer et al. Arthritis Rheum 2002;46:1408–1409.
   Google Scholar